TCE

QCR Holdings, Inc. Announces Net Income of $26.7 Million for the First Quarter of 2024

Retrieved on: 
火曜日, 4月 23, 2024
Sale, Central Time, Housing, News, TCE, Webcast, NIM, LIHTC, NPAS, GAAP, Growth, QCR Holdings, Bank

MOLINE, Ill., April 23, 2024 (GLOBE NEWSWIRE) -- QCR Holdings, Inc. (NASDAQ: QCRH) (the “Company”) today announced quarterly net income of $26.7 million and diluted earnings per share (“EPS”) of $1.58 for the first quarter of 2024, compared to net income of $32.9 million and diluted EPS of $1.95 for the fourth quarter of 2023.

Key Points: 
  • Net interest income for the first quarter of 2024 totaled $54.7 million, a decrease of $1.0 million from the fourth quarter of 2023.
  • However, the Company’s net interest income driven by core activity saw growth of approximately $1.2 million during the first quarter, led by continued expansion in loan and investment yields.
  • The Company generated $16.5 million of capital markets revenue in the quarter, as compared to the record $37.0 million in the prior quarter.
  • Wealth management revenue was $4.3 million for the quarter, up 16% on an annualized basis from $4.1 million in the prior quarter.

CDR-Life to Present Tumor Targeting Capabilities of M-gager® Platform at the TCR-Based Therapies for Solid Tumors Summit

Retrieved on: 
火曜日, 4月 23, 2024
TCE, MHC, Antibody

ZÜRICH, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced a presentation on its proprietary antibody-major histocompatibility complex (MHC) technology for the development of highly specific T-cell engagers (TCE) at the TCR-Based Therapies for Solid Tumors Summit, occurring April 23-25 in Boston, Massachusetts.

Key Points: 
  • ZÜRICH, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced a presentation on its proprietary antibody-major histocompatibility complex (MHC) technology for the development of highly specific T-cell engagers (TCE) at the TCR-Based Therapies for Solid Tumors Summit, occurring April 23-25 in Boston, Massachusetts.
  • The presentation will discuss how antibodies targeting tumor peptides on the MHC enable T-cells access to an untapped reservoir of intracellular tumor antigens and will highlight the M-gager® technology’s ability to leverage the potency, versatility and manufacturability of antibodies to revolutionize cancer immunotherapy.

Bank of Marin Bancorp Reports First Quarter Earnings of $2.9 Million

Retrieved on: 
月曜日, 4月 29, 2024
Banking, Professional Services, Finance, Sale, Federal Reserve, Investment, FHLB, Capital, Risk, Bank holding company, TCE, Federal, Moody's Analytics, Pressure, Growth, Bank

Bank of Marin Bancorp, "Bancorp" (Nasdaq: BMRC), parent company of Bank of Marin, "Bank," announced earnings of $2.9 million for the first quarter of 2024, compared to $610 thousand for the fourth quarter of 2023 and $9.4 million for the first quarter of 2023.

Key Points: 
  • Bank of Marin Bancorp, "Bancorp" (Nasdaq: BMRC), parent company of Bank of Marin, "Bank," announced earnings of $2.9 million for the first quarter of 2024, compared to $610 thousand for the fourth quarter of 2023 and $9.4 million for the first quarter of 2023.
  • Diluted earnings per share were $0.18 for the first quarter, compared to $0.04 for the prior quarter and $0.59 for the first quarter of 2023.
  • Loan originations for the first quarter were $12.4 million, compared to $53.8 million for the fourth quarter of 2023.
  • Loan payoffs were $21.8 million for the first quarter, compared to $50.3 million for the fourth quarter of 2023.

FVCBankcorp, Inc. Announces First Quarter 2024 Earnings; Net Interest Income and Margin Improvement

Retrieved on: 
火曜日, 4月 23, 2024
Banking, Professional Services, Finance, Well, Sale, Table, Policy, Commercial, IntraFi Network, TCE, ACL, History, Net interest income, Environment, Bank, FDIC, GAAP, Growth, Cryptocurrency

Net interest margin increased 10 basis points, or 4%, to 2.47% for the first quarter of 2024, compared to 2.37% for the fourth quarter of 2023.

Key Points: 
  • Net interest margin increased 10 basis points, or 4%, to 2.47% for the first quarter of 2024, compared to 2.37% for the fourth quarter of 2023.
  • Net interest income increased $133 thousand to $12.8 million, or 1%, compared to $12.7 million for the fourth quarter of 2023.
  • The Company recorded net recoveries of $30 thousand during the first quarter of 2024, or 0.01% of average total loans.
  • The full impact of the surrender to net interest income will be realized during the second quarter of 2024.

First Internet Bancorp Reports First Quarter 2024 Results

Retrieved on: 
水曜日, 4月 24, 2024
Banking, Professional Services, Sale, Small business, U.S. Bancorp, FTE, BP, TCE, Fintech, As a service, Partnership, SBA, ACL, Compact disc, Webcast, NIM, First Internet Bancorp, Bank, Ratio, AOCI, Marketing, Advertising, Small Business Administration, Telephone, First, Growth

First Internet Bancorp (the “Company”) (Nasdaq: INBK), the parent company of First Internet Bank (the “Bank”), announced today financial and operational results for the first quarter ended March 31, 2024.

Key Points: 
  • First Internet Bancorp (the “Company”) (Nasdaq: INBK), the parent company of First Internet Bank (the “Bank”), announced today financial and operational results for the first quarter ended March 31, 2024.
  • Total interest income for the first quarter of 2024 was $68.2 million, an increase of 2.9% compared to the fourth quarter of 2023, and an increase of 31.0% compared to the first quarter of 2023.
  • The cost of interest-bearing deposits was 4.25% for the first quarter of 2024, compared to 4.14% for the fourth quarter of 2023.
  • Noninterest income for the first quarter of 2024 was $8.3 million, compared to $7.4 million for the fourth quarter of 2023, and $5.4 million for the first quarter of 2023.

Independent Bank Group, Inc. Reports First Quarter Financial Results and Declares Quarterly Dividend

Retrieved on: 
月曜日, 4月 22, 2024
Banking, Professional Services, Finance, Sale, Total, FHLB, Federal funds, TCE, Environment, Bank statement, Growth

Net interest income was $103.0 million for first quarter 2024 compared to $127.9 million for first quarter 2023 and $106.3 million for fourth quarter 2023.

Key Points: 
  • Net interest income was $103.0 million for first quarter 2024 compared to $127.9 million for first quarter 2023 and $106.3 million for fourth quarter 2023.
  • The yield on interest-earning assets was 5.53% for first quarter 2024 compared to 4.98% for first quarter 2023 and 5.44% for fourth quarter 2023.
  • The net interest margin was 2.42% for first quarter 2024 compared to 3.17% for first quarter 2023 and 2.49% for fourth quarter 2023.
  • Total noninterest expense decreased $100.9 million compared to first quarter 2023 and decreased $6.7 million compared to fourth quarter 2023.

Hancock Whitney Reports First Quarter 2024 EPS of $1.24

Retrieved on: 
火曜日, 4月 16, 2024
Professional Services, Other Professional Services, Finance, Asset Management, Consulting, Banking, Personal Finance, Sale, Total, Common, Central Time, TCE, Insurance, HWC, Trust, ACL, ATM, NIM, DDA, EPS, Share repurchase, Credit, Growth, Q&A, Video game

Hancock Whitney Corporation (Nasdaq: HWC) today announced its financial results for the first quarter of 2024.

Key Points: 
  • Hancock Whitney Corporation (Nasdaq: HWC) today announced its financial results for the first quarter of 2024.
  • Net income for the first quarter of 2024 totaled $108.6 million, or $1.24 per diluted common share (EPS), compared to $50.6 million, or $0.58 per diluted common share, in the fourth quarter of 2023.
  • Noninterest income totaled $87.9 million for the first quarter of 2024, up $48.9 million, or 126%, from the fourth quarter of 2023.
  • Other noninterest income was $13.2 million in the first quarter of 2024, compared to $32.0 million in the fourth quarter of 2023.

Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting

Retrieved on: 
月曜日, 4月 8, 2024
Well, Small-cell carcinoma, Therapeutic index, Glomus tumor, Endometrial cancer, Survival, Environment, Service provider, Trichloroethylene, Patient, Primate, Triple-negative breast cancer, Lead, Zymeworks, 3D, Standard of care, Cancer, TAA, Spacecraft, Lung cancer, IND, CD3, DLL3, AACR, Workflow, Antibody, TCE, CD28, Therapy, Stomach, ADC, Vaccine

The compelling preclinical activity profile supports ZW191 development across multiple tumor types, including FRα-high/mid/low ovarian cancers and other FRα-expressing indications, including non-small cell lung cancer, endometrial cancer, and triple-negative breast cancer.

Key Points: 
  • The compelling preclinical activity profile supports ZW191 development across multiple tumor types, including FRα-high/mid/low ovarian cancers and other FRα-expressing indications, including non-small cell lung cancer, endometrial cancer, and triple-negative breast cancer.
  • An investigational new drug (IND) submission or foreign equivalent is planned for 2024.
  • Small cell lung cancer (SCLC) is an aggressive neuroendocrine cancer with a poor prognosis and high unmet medical need2.
  • Displays no cross-linking of T cells and exhibits obligate cis T cell binding of CD28, requiring co-engagement of CD3.

CDR-Life Unveils Results on T-Cell Engagers Targeting Hard-to-Treat Solid Tumors at AACR 2024

Retrieved on: 
金曜日, 4月 5, 2024
Cell, Trichloroethylene, Patient, Lung, Epitope, Breast, KK, Allele, AACR, Cancer, Antibody, TCE, Therapy, Peptide, Vaccine

Identifying a TCE against the KK-LC-1 peptide on HLA-A*01 will provide an option for patients that do not benefit from the more common HLA-A*02 targeting therapeutics currently in development.

Key Points: 
  • Identifying a TCE against the KK-LC-1 peptide on HLA-A*01 will provide an option for patients that do not benefit from the more common HLA-A*02 targeting therapeutics currently in development.
  • However, high levels of similar off-target peptides presented in healthy tissues make targeting the KK-LC-1/HLA-A*01 challenging.
  • CDR-Life’s data gathered on pMHC TCE antibodies with high specificity towards HLA-A*01 restricted KK-LC-1 epitopes demonstrate the antibodies’ promising anti-tumor activity and specificity for KK-LC-1/HLA-A*01 positive tumors.
  • In vitro studies showed significantly higher TCE-dependent T-cell activation towards cells presenting the target peptide compared to the risk peptides.

TEN Ltd. Reports Record Profits for Year-End and Fourth Quarter 2023 Results and Dividend of $0.60 per Common Share

Retrieved on: 
水曜日, 3月 27, 2024
Employment, Growth, Environment, Depreciation, TNP, Interest, TCE, LNG, LR2, Cryptocurrency

Greece, March 27, 2024 (GLOBE NEWSWIRE) -- TEN, Ltd. (TEN) (NYSE: TNP) (the “Company”) reports results (unaudited) for the fourth quarter and the year ended December 31, 2023.

Key Points: 
  • Greece, March 27, 2024 (GLOBE NEWSWIRE) -- TEN, Ltd. (TEN) (NYSE: TNP) (the “Company”) reports results (unaudited) for the fourth quarter and the year ended December 31, 2023.
  • The Company’s total debt obligations were reduced from the 2022 level and settled at $1.56 billion at December 31, 2023.
  • This elevated rate environment resulted to an increase of interest income from $2 million in 2022 to $15 million in 2023.
  • Fleet utilization reached 98.3% in the fourth quarter of 2023 from a still high 97.4% in the 2022 fourth quarter due to the increase of vessels in time-charter employment.